Practical considerations for chimeric antigen receptor design and delivery

References

• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024–10028.
   PubMed Web of Science ®Google Scholar
• Van Oers NS, Von Boehmer H, Weiss A. The pre-T cell receptor (TCR) complex is functionally coupled to the TCR-zeta subunit. J Exp Med. 1995;182:1585–1590.
   PubMed Web of Science ®Google Scholar
• Hibbs ML, Selvaraj P, Carpen O, et al. Mechanisms for regulating expression of membrane isoforms of Fc gamma RIII (CD16). Science. 1989;246:1608–1611.
   PubMed Web of Science ®Google Scholar
• Reth M. Antigen receptor tail clue. Nature. 1989;338:383–384.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720–724.
   PubMed Web of Science ®Google Scholar
• Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 1993;178:361–366.
   PubMed Web of Science ®Google Scholar
• Heuser C, Hombach A, Losch C, et al. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. Gene Ther. 2003;10:1408–1419.
   PubMed Web of Science ®Google Scholar
• Ren-Heidenreich L, Mordini R, Hayman GT, et al. Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. Cancer Immunol Immunother. 2002;51:417–423.
   PubMed Web of Science ®Google Scholar
• Roberts MR, Cooke KS, Tran AC, et al. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunology. 1998;161:375–384.
   PubMed Web of Science ®Google Scholar
• Letourneur F, Klausner RD. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci U S A. 1991;88:8905–8909.
   PubMed Web of Science ®Google Scholar
• Haynes NM, Snook MB, Trapani JA, et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunology. 2001;166:182–187.
   PubMed Web of Science ®Google Scholar
• Kersh EN, Kersh GJ, Allen PM. Partially phosphorylated T cell receptor zeta molecules can inhibit T cell activation. J Exp Med. 1999;190:1627–1636.
   PubMed Web of Science ®Google Scholar
• Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell. 1991;64:1037–1046.
   PubMed Web of Science ®Google Scholar
• Nolan KF, Yun CO, Akamatsu Y, et al. Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res. 1999;5:3928–3941.
   PubMed Web of Science ®Google Scholar
• Fitzer-Attas CJ, Schindler DG, Waks T, et al. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J Immunology. 1998;160:145–154.
   PubMed Web of Science ®Google Scholar
• Kolanus W, Romeo C, Seed B. T cell activation by clustered tyrosine kinases. Cell. 1993;74:171–183.
   PubMed Web of Science ®Google Scholar
• Fitzer-Attas CJ, Schindler DG, Waks T, et al. Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation. J Biol Chem. 1997;272:8551–8557.
   PubMed Web of Science ®Google Scholar
• Marin V, Kakuda H, Dander E, et al. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol. 2007;35:1388–1397.
   PubMed Web of Science ®Google Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106:376–383.
   PubMed Web of Science ®Google Scholar
• Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 2005;106:1544–1551.
   PubMed Web of Science ®Google Scholar
• Topfer K, Cartellieri M, Michen S, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194:3201–3212.
   PubMed Web of Science ®Google Scholar
• Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445–480.
   PubMed Web of Science ®Google Scholar
• Brocker T. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 2000;96:1999–2001.
   PubMed Web of Science ®Google Scholar
• Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181:1653–1659.
   PubMed Web of Science ®Google Scholar
• Van Lier RA, Borst J, Vroom TM, et al. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunology. 1987;139:1589–1596.
   PubMed Web of Science ®Google Scholar
• Ochsenbein AF, Riddell SR, Brown M, et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med. 2004;200:1407–1417.
   PubMed Web of Science ®Google Scholar
• Hendriks J, Gravestein LA, Tesselaar K, et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol. 2000;1:433–440.
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Poussin M, et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 2012;119:696–706.
   PubMed Web of Science ®Google Scholar
• Barber A, Sentman CL. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J Immunol. 2009;183:2365–2372.
   PubMed Web of Science ®Google Scholar
• Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol. 2013;190:2455–2463.
   PubMed Web of Science ®Google Scholar
• Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 2006;66:5927–5933.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426–5435.
   PubMed Web of Science ®Google Scholar
• Chang YH, Connolly J, Shimasaki N, et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73:1777–1786.
   PubMed Web of Science ®Google Scholar
• Duong CP, Westwood JA, Yong CS, et al. Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. Plos One. 2013;8:e63037.
   PubMed Web of Science ®Google Scholar
• Foster AE, Chang P, Lin P-Y, et al. MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells. J Clin Oncol. 2015;33:3064.
   Web of Science ®Google Scholar
• Altvater B, Landmeier S, Pscherer S, et al. 2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells. Cancer Immunol Immunother. 2009;58:1991–2001.
   PubMed Web of Science ®Google Scholar
• Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996;273:104–106.
   PubMed Web of Science ®Google Scholar
• Riley JL, Mao M, Kobayashi S, et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci U S A. 2002;99:11790–11795.
   PubMed Web of Science ®Google Scholar
• Diehn M, Alizadeh AA, Rando OJ, et al. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc Natl Acad Sci U S A. 2002;99:11796–11801.
   PubMed Web of Science ®Google Scholar
• Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A. 1989;86:1333–1337.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121:1822–1826.
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106:3360–3365.
   PubMed Web of Science ®Google Scholar
• Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002;20:70–75.
   PubMed Web of Science ®Google Scholar
• Finney HM, Lawson AD, Bebbington CR, et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunology. 1998;161:2791–2797.
   PubMed Web of Science ®Google Scholar
• Loskog A, Giandomenico V, Rossig C, et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia. 2006;20:1819–1828.
   PubMed Web of Science ®Google Scholar
• Santoro SP, Kim S, Motz GT, et al. T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol Res. 2015;3:68–84.
   PubMed Web of Science ®Google Scholar
• Zhong XS, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18:413–420.
   PubMed Web of Science ®Google Scholar
• Schwarz H, Tuckwell J, Lotz M. A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene. 1993;134:295–298.
   PubMed Web of Science ®Google Scholar
• Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol. 2001;167:1313–1324.
   PubMed Web of Science ®Google Scholar
• Cooper D, Bansal-Pakala P, Croft M. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur J Immunol. 2002;32:521–529.
   PubMed Web of Science ®Google Scholar
• Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunology. 1999;162:5037–5040.
   PubMed Web of Science ®Google Scholar
• Lee HW, Nam KO, Seo SK, et al. 4-1BB cross-linking enhances the survival and cell cycle progression of CD4 T lymphocytes. Cell Immunol. 2003;223:143–150.
   PubMed Web of Science ®Google Scholar
• Habib-Agahi M, Phan TT, Searle PF. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol. 2007;19:1383–1394.
   PubMed Web of Science ®Google Scholar
• Tan JT, Whitmire JK, Murali-Krishna K, et al. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol. 2000;164:2320–2325.
   PubMed Web of Science ®Google Scholar
• Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186:47–55.
   PubMed Web of Science ®Google Scholar
• Bertram EM, Lau P, Watts TH. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol. 2002;168:3777–3785.
   PubMed Web of Science ®Google Scholar
• Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18:676–684.
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–590.
   PubMed Web of Science ®Google Scholar
• Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17:1453–1464.
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011;71:4617–4627.
   PubMed Web of Science ®Google Scholar
• Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66:10995–11004.
   PubMed Web of Science ®Google Scholar
• Tammana S, Huang X, Wong M, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther. 2010;21:75–86.
   PubMed Web of Science ®Google Scholar
• Guedan S, Chen X, Madar A, et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood. 2014;124:1070–1080.
   PubMed Web of Science ®Google Scholar
• Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 2007;18:712–725.
   PubMed Web of Science ®Google Scholar
• Van Der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14:499–509.
   PubMed Web of Science ®Google Scholar
• Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes–a molecule related to nerve growth factor receptor. Embo J. 1990;9:1063–1068.
   PubMed Web of Science ®Google Scholar
• Gramaglia I, Weinberg AD, Lemon M, et al. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunology. 1998;161:6510–6517.
   PubMed Web of Science ®Google Scholar
• Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004;172:104–113.
   PubMed Web of Science ®Google Scholar
• Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer. 2011;129:2935–2944.
   PubMed Web of Science ®Google Scholar
• Pule MA, Straathof KC, Dotti G, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12:933–941.
   PubMed Web of Science ®Google Scholar
• Wilkie S, Picco G, Foster J, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180:4901–4909.
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112:362–373.
   PubMed Web of Science ®Google Scholar
• Paulos CM, Carpenito C, Plesa G, et al. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med. 2010;2:55ra78.
   PubMed Web of Science ®Google Scholar
• Muranski P, Borman ZA, Kerkar SP, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 2011;35:972–985.
   PubMed Web of Science ®Google Scholar
• Shen CJ, Yang YX, Han EQ, et al. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J Hematol Oncol. 2013;6:33.
   PubMed Web of Science ®Google Scholar
• Turatti F, Figini M, Balladore E, et al. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother. 2007;30:684–693.
   PubMed Web of Science ®Google Scholar
• Patel SD, Moskalenko M, Smith D, et al. Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther. 1999;6:412–419.
   PubMed Web of Science ®Google Scholar
• Stancovski I, Schindler DG, Waks T, et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunology. 1993;151:6577–6582.
   PubMed Web of Science ®Google Scholar
• Geiger TL, Nguyen P, Leitenberg D, et al. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood. 2001;98:2364–2371.
   PubMed Web of Science ®Google Scholar
• Bridgeman JS, Ladell K, Sheard VE, et al. CD3zeta-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy. Clin Exp Immunol. 2014;175:258–267.
   PubMed Web of Science ®Google Scholar
• Annenkov AE, Moyes SP, Eshhar Z, et al. Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonRI-signaling gamma subunit. J Immunology. 1998;161:6604–6613.
   PubMed Web of Science ®Google Scholar
• Krug C, Birkholz K, Paulus A, et al. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone. Cancer Immunol Immunother. 2015;64:1623–1635.
   PubMed Web of Science ®Google Scholar
• Dotti G, Gottschalk S, Savoldo B, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257:107–126.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–1518.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10:267–276.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Curran KJ. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology Am Soc Hematol Educ Program. 2012;2012:143–151.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099–4102.
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Jena B, Bollard CM. Good T cells for bad B cells. Blood. 2012;119:2700–2702.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wu MR, Sentman CL. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol. 2012;189:2290–2299.
   PubMed Web of Science ®Google Scholar
• Kahlon KS, Brown C, Cooper LJ, et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64:9160–9166.
   PubMed Web of Science ®Google Scholar
• Jensen M, Tan G, Forman S, et al. CD20 is a molecular target for scFvFc: zetareceptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant. 1998;4:75–83.
   PubMedGoogle Scholar
• Choudhuri K, Wiseman D, Brown MH, et al. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Nature. 2005;436:578–582.
   PubMed Web of Science ®Google Scholar
• Bridgeman JS, Hawkins RE, Bagley S, et al. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol. 2010;184:6938–6949.
   PubMed Web of Science ®Google Scholar
• Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16:1245–1256.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Bajgain P, Sukumaran S, et al. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016;5:e1253656.
   PubMed Web of Science ®Google Scholar
• Almasbak H, Walseng E, Kristian A, et al. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther. 2015;22:391–403.
   PubMed Web of Science ®Google Scholar
• Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Ther. 2010;17:1206–1213.
   PubMed Web of Science ®Google Scholar
• Hudecek M, Lupo-Stanghellini MT, Kosasih PL, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19:3153–3164.
   PubMed Web of Science ®Google Scholar
• Hudecek M, Sommermeyer D, Kosasih PL, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3:125–135.
   PubMed Web of Science ®Google Scholar
• Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28:203–211.
   PubMed Web of Science ®Google Scholar
• Moritz D, Groner B. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther. 1995;2:539–546.
   PubMed Web of Science ®Google Scholar
• James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180:7028–7038.
   PubMed Web of Science ®Google Scholar
• Hombach AA, Schildgen V, Heuser C, et al. T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol. 2007;178:4650–4657.
   PubMed Web of Science ®Google Scholar
• Schonfeld K, Sahm C, Zhang C, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23:330–338.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009;183:5563–5574.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000 Feb 29. [cited 2017 May]. http://clinicaltrials.gov/
   Google Scholar
• Turtle CJ, Hanafi L-A, Berger C, et al. CD19 CAR–T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–2138.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Laetsch TW, Buechner J, et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood. 2016;128:221.
   Web of Science ®Google Scholar
• Shah BD, Wierda WG, Schiller GJ, et al. Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL). J Clinical Oncolo. 2017;35(suppl):3024.
   Google Scholar
• Park JH, Riviere I, Wang X, et al. Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy. J Clinical Oncolo. 2017;7008:35.
   Google Scholar
• Gardner RA, Finney O, Annesley C, et al. Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;blood-2017-02-769208.
   Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Nasta SD, et al. Treatment with chimeric antigen receptor modified T cells directed against CD19 (CTL019) results in durable remissions in patients with relapsed or refractory diffuse large B cell lymphomas of germinal center and non-germinal center origin, “double hit” diffuse large B cell lymphomas, and transformed follicular to diffuse large B cell lymphomas. Blood. 2016;128:3026.
   PubMed Web of Science ®Google Scholar
• Da Silva DG, Mukherjee M, Srinivasan M, et al. Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with B-cell lymphoma: reversal of toxicity from tonic signaling. Blood. 2016;128:1851.
   Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Kte-C19 (anti-CD19 CAR T Cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 Zuma-1. Blood. 2016;128:LBA-6.
   Google Scholar
• Chong EA, Svoboda J, Nasta SD, et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with poor prognosis, relapsed or refractory CD19+ follicular lymphoma: prolonged remissions relative to antecedent therapy. Blood. 2016;128:1100.
   Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al.(2016). A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. Blood. 2016;128:998.
   Google Scholar
• Garfall AL, Stadtmauer EA, Maus MV, et al. Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma. Blood. 2016;128:974.
   Web of Science ®Google Scholar
• Turtle CJ, Hanafi L-A, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells. Sci Transl Med. 2016;8:355ra116–355ra116.
   PubMed Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Clinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL). J Clinical Oncolo. 2017;35(suppl):7512-7512.
   Web of Science ®Google Scholar
• Brudno JN, Shi V, Stroncek D, et al. T cells expressing a novel fully-human anti-CD19 chimeric antigen receptor induce remissions of advanced lymphoma in a first-in-humans clinical trial. Blood. 2016;128:999.
   Google Scholar
• Maude SL, Barrett DM, Rheingold SR, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. Blood. 2016;128:217.
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Lin Y, Raje NS, et al. First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: updated results. J Clinical Oncolo. 2017;35(suppl):3010.
   Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, et al. B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study. Blood. 2016;128:1147.
   Web of Science ®Google Scholar
• Shah NN, Stetler-Stevenson M, Yuan CM, et al. Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood. 2016;128:650.
   Google Scholar
• Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017. [Epub ahead of print].
   Web of Science ®Google Scholar
• Nikiforow S, Werner L, Murad J, et al. Safety data from a first-in-human phase 1 trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma. Blood. 2016;128:4052.
   PubMed Web of Science ®Google Scholar
• Caruso HG, Hurton LV, Najjar A, et al. Tuning Sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75:3505–3518.
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang S, Fang C, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 2015;75:3596–3607.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach A, Heuser C, et al. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004;173:7647–7653.
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Poussin M, et al. A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget. 2015;6:21533–21546.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843–851.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, Van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21:904–912.
   PubMed Web of Science ®Google Scholar
• Lynn RC, Feng Y, Schutsky K, et al. High-affinity FRbeta-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia. 2016;30:1355–1364.
   PubMed Web of Science ®Google Scholar
• Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigen-binding proteins. Science. 1988;242:423–426.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Gratama JW, Warnaar SO, et al. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int J Cancer. 1995;60:450–457.
   PubMed Web of Science ®Google Scholar
• Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1:26–31.
   PubMed Web of Science ®Google Scholar
• Bumbaca D, Wong A, Drake E, et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs. 2011;3:376–386.
   PubMed Web of Science ®Google Scholar
• Feyen O, Lueking A, Kowald A, et al. Off-target activity of TNF-alpha inhibitors characterized by protein biochips. Anal Bioanal Chem. 2008;391:1713–1720.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368:652–665.
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett DM, Ambrose DE, et al. Efficacy and safety of humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 in children with relapsed/refractory ALL. Blood. 2015;126:683.
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Santoro S, et al. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum Gene Ther. 2013;24:295–305.
   PubMed Web of Science ®Google Scholar
• Barber A, Zhang T, Megli CJ, et al. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol. 2008;36:1318–1328.
   PubMed Web of Science ®Google Scholar
• Barber A, Meehan KR, Sentman CL. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther. 2011;18:509–516.
   PubMed Web of Science ®Google Scholar
• Lehner M, Gotz G, Proff J, et al. Redirecting T cells to Ewing’s sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. Plos One. 2012;7:e31210.
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A. 2001;98:11521–11526.
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Jensen ER, Jamieson AM, et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413:165–171.
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Jamieson AM, Liu SD, et al. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1:119–126.
   PubMed Web of Science ®Google Scholar
• Jamieson AM, Diefenbach A, McMahon CW, et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity. 2002;17:19–29.
   PubMed Web of Science ®Google Scholar
• Sentman ML, Murad JM, Cook WJ, et al. Mechanisms of acute toxicity in NKG2D chimeric antigen receptor T cell-treated mice. J Immunol. 2016;197:4674–4685.
   PubMed Web of Science ®Google Scholar
• VanSeggelen H, Hammill JA, Dvorkin-Gheva A, et al. T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice. Mol Ther. 2015;23:1600–1610.
   PubMed Web of Science ®Google Scholar
• Krebs S, Chow KK, Yi Z, et al. T cells redirected to interleukin-13Ralpha2 with interleukin-13 mutein–chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ralpha1. Cytotherapy. 2014;16:1121–1131.
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21:4062–4072.
   PubMed Web of Science ®Google Scholar
• Brown CE, Starr R, Aguilar B, et al. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells. Clin Cancer Res. 2012;18:2199–2209.
   PubMed Web of Science ®Google Scholar
• Shaffer DR, Zhou P, Gottschalk S. Foreign or domestic CARs: receptor ligands as antigen-binding domains. Med Sci. 2014;2:23–36.
   Google Scholar
• Oren R, Hod-Marco M, Haus-Cohen M, et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol. 2014;193:5733–5743.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Ahmed M, Tassev DV, et al. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia. 2015;29:2238–2247.
   PubMed Web of Science ®Google Scholar
• Willemsen RA, Debets R, Hart E, et al. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther. 2001;8:1601–1608.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Purdon TJ, Daniyan AF, et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen. Leukemia. 2017.[Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Pancer Z, Amemiya CT, Ehrhardt GR, et al. Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey. Nature. 2004;430:174–180.
   PubMed Web of Science ®Google Scholar
• Mariuzza RA, Velikovsky CA, Deng L, et al. Structural insights into the evolution of the adaptive immune system: the variable lymphocyte receptors of jawless vertebrates. Biol Chem. 2010;391:753–760.
   PubMed Web of Science ®Google Scholar
• Moot R, Raikar SS, Fleischer L, et al. Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors. Mol Ther Oncolytics. 2016;3:16026.
   PubMed Web of Science ®Google Scholar
• Liechtenstein T, Perez-Janices N, Escors D. Lentiviral vectors for cancer immunotherapy and clinical applications. Cancers (Basel). 2013;5:815–837.
   PubMedGoogle Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415–419.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255–256.
   PubMed Web of Science ®Google Scholar
• Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity. Sci Transl Med. 2014;6:227ra33.
   PubMed Web of Science ®Google Scholar
• Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16:198–204.
   PubMed Web of Science ®Google Scholar
• Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4:132ra53.
   PubMed Web of Science ®Google Scholar
• Thornhill SI, Schambach A, Howe SJ, et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther. 2008;16:590–598.
   PubMed Web of Science ®Google Scholar
• Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009;17:1919–1928.
   PubMed Web of Science ®Google Scholar
• Zychlinski D, Schambach A, Modlich U, et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther. 2008;16:718–725.
   PubMed Web of Science ®Google Scholar
• Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood. 2006;108:2545–2553.
   PubMed Web of Science ®Google Scholar
• Avedillo Diez I, Zychlinski D, Coci EG, et al. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm. 2011;8:1525–1537.
   PubMed Web of Science ®Google Scholar
• Dai H, Wang Y, Lu X, et al. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108:djv439.
   PubMedGoogle Scholar
• Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123:2625–2635.
   PubMed Web of Science ®Google Scholar
• Vectors used in gene therapy clinical trials. J Gene Med. John Wiley & Sons. April 2017. [cited April 2017]. http://www.wiley.com/legacy/wileychi/genmed/clinical/ .
   Google Scholar
• Cattoglio C, Pellin D, Rizzi E, et al. High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood. 2010;116:5507–5517.
   PubMed Web of Science ®Google Scholar
• Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24:687–696.
   PubMed Web of Science ®Google Scholar
• Wang GP, Levine BL, Binder GK, et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther. 2009;17:844–850.
   PubMed Web of Science ®Google Scholar
• Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest. 2009;119:964–975.
   PubMed Web of Science ®Google Scholar
• Hematti P, Hong BK, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. Plos Biol. 2004;2:e423.
   PubMed Web of Science ®Google Scholar
• Maruggi G, Porcellini S, Facchini G, et al. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol Ther. 2009;17:851–856.
   PubMed Web of Science ®Google Scholar
• Biffi A, Bartolomae CC, Cesana D, et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood. 2011;117:5332–5339.
   PubMed Web of Science ®Google Scholar
• Cattoglio C, Facchini G, Sartori D, et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood. 2007;110:1770–1778.
   PubMed Web of Science ®Google Scholar
• Almarza D, Bussadori G, Navarro M, et al. Risk assessment in skin gene therapy: viral-cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectors. Gene Ther. 2011;18:674–681.
   PubMed Web of Science ®Google Scholar
• Moiani A, Paleari Y, Sartori D, et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest. 2012;122:1653–1666.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 2010;467:318–322.
   PubMed Web of Science ®Google Scholar
• McGarrity GJ, Hoyah G, Winemiller A, et al. Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med. 2013;15:78–82.
   PubMed Web of Science ®Google Scholar
• Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol. 1994;68:510–516.
   PubMed Web of Science ®Google Scholar
• Bukrinsky MI, Haggerty S, Dempsey MP, et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature. 1993;365:666–669.
   PubMed Web of Science ®Google Scholar
• Pfeifer A, Ikawa M, Dayn Y, et al. Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci U S A. 2002;99:2140–2145.
   PubMed Web of Science ®Google Scholar
• Lois C, Hong EJ, Pease S, et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002;295:868–872.
   PubMed Web of Science ®Google Scholar
• Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A. 2006;103:17372–17377.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112–120.
   PubMed Web of Science ®Google Scholar
• Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370:901–910.
   PubMed Web of Science ®Google Scholar
• Trobridge GD, Miller DG, Jacobs MA, et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci U S A. 2006;103:1498–1503.
   PubMed Web of Science ®Google Scholar
• Trobridge G, Russell DW. Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol. 2004;78:2327–2335.
   PubMed Web of Science ®Google Scholar
• Bauer TR Jr., Allen JM, Hai M, et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med. 2008;14:93–97.
   PubMed Web of Science ®Google Scholar
• Zincarelli C, Soltys S, Rengo G, et al. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16:1073–1080.
   PubMed Web of Science ®Google Scholar
• Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol. 1996;70:3235–3241.
   PubMed Web of Science ®Google Scholar
• Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther. 2000;1:49–55.
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. 2003;101:1637–1644.
   PubMed Web of Science ®Google Scholar
• Ivics Z, Izsvak Z, Minter A, et al. Identification of functional domains and evolution of Tc1-like transposable elements. Proc Natl Acad Sci U S A. 1996;93:5008–5013.
   PubMed Web of Science ®Google Scholar
• Ivics Z, Hackett PB, Plasterk RH, et al. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997;91:501–510.
   PubMed Web of Science ®Google Scholar
• Jin Z, Maiti S, Huls H, et al. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther. 2011;18:849–856.
   PubMed Web of Science ®Google Scholar
• Luo G, Ivics Z, Izsvak Z, et al. Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells. Proc Natl Acad Sci U S A. 1998;95:10769–10773.
   PubMed Web of Science ®Google Scholar
• Yant SR, Meuse L, Chiu W, et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet. 2000;25:35–41.
   PubMed Web of Science ®Google Scholar
• Wilber A, Linehan JL, Tian X, et al. Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells. 2007;25:2919–2927.
   PubMed Web of Science ®Google Scholar
• Sjeklocha LM, Wong PY, Belcher JD, et al. Beta-globin sleeping beauty transposon reduces red blood cell sickling in a patient-derived CD34(+)-based in vitro model. Plos One. 2013;8:e80403.
   PubMed Web of Science ®Google Scholar
• Zayed H, Izsvak Z, Walisko O, et al. Development of hyperactive sleeping beauty transposon vectors by mutational analysis. Mol Ther. 2004;9:292–304.
   PubMed Web of Science ®Google Scholar
• Huang X, Guo H, Kang J, et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther. 2008;16:580–589.
   PubMed Web of Science ®Google Scholar
• Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68:2961–2971.
   PubMed Web of Science ®Google Scholar
• Maiti SN, Huls H, Singh H, et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother. 2013;36:112–123.
   PubMed Web of Science ®Google Scholar
• Singh H, Moyes JS, Huls MH, et al. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther. 2015;22:95–100.
   PubMed Web of Science ®Google Scholar
• Huang G, Yu L, Cooper LJ, et al. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 2012;72:271–281.
   PubMed Web of Science ®Google Scholar
• Kumaresan PR, Manuri PR, Albert ND, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A. 2014;111:10660–10665.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012;23:444–450.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Singh H, Huls MH, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016;126:3363–3376.
   PubMed Web of Science ®Google Scholar
• Xue X, Huang X, Nodland SE, et al. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood. 2009;114:1319–1330.
   PubMed Web of Science ®Google Scholar
• Liu G, Geurts AM, Yae K, et al. Target-site preferences of Sleeping Beauty transposons. J Mol Biol. 2005;346:161–173.
   PubMed Web of Science ®Google Scholar
• Wu SC, Meir YJ, Coates CJ, et al. piggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2, and Mos1 in mammalian cells. Proc Natl Acad Sci U S A. 2006;103:15008–15013.
   PubMed Web of Science ®Google Scholar
• Nakazawa Y, Huye LE, Dotti G, et al. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother. 2009;32:826–836.
   PubMed Web of Science ®Google Scholar
• Nakazawa Y, Huye LE, Salsman VS, et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011;19:2133–2143.
   PubMed Web of Science ®Google Scholar
• Wilson MH, Coates CJ, George AL Jr. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther. 2007;15:139–145.
   PubMed Web of Science ®Google Scholar
• Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010;21:427–437.
   PubMed Web of Science ®Google Scholar
• Ramanayake S, Bilmon I, Bishop D, et al. Low-cost generation of good manufacturing practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. Cytotherapy. 2015;17:1251–1267.
   PubMed Web of Science ®Google Scholar
• Saito S, Nakazawa Y, Sueki A, et al. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy. 2014;16:1257–1269.
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur M, Wels WS, et al. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res. 2009;33:1255–1259.
   PubMed Web of Science ®Google Scholar
• Choi Y, Yuen C, Maiti SN, et al. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices. 2010;12:855–863.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zheng Z, Cohen CJ, et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther. 2006;13:151–159.
   PubMed Web of Science ®Google Scholar
• Li L, Liu LN, Feller S, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 2010;17:147–154.
   PubMed Web of Science ®Google Scholar
• Almasbak H, Rian E, Hoel HJ, et al. Transiently redirected T cells for adoptive transfer. Cytotherapy. 2011;13:629–640.
   PubMed Web of Science ®Google Scholar
• Birkholz K, Hombach A, Krug C, et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 2009;16:596–604.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Zhao Y, Liu X, et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther. 2011;22:1575–1586.
   PubMed Web of Science ®Google Scholar
• Yoon SH, Lee JM, Cho HI, et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther. 2009;16:489–497.
   PubMed Web of Science ®Google Scholar
• Rabinovich PM, Komarovskaya ME, Wrzesinski SH, et al. Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Hum Gene Ther. 2009;20:51–61.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010;70:9053–9061.
   PubMed Web of Science ®Google Scholar
• Investors & Media. BluebirdBio. 2017. [cited 2017 May]. http://investor.bluebirdbio.com/.
   Google Scholar
• Investor Relations. Kite Pharma Inc. 2017. [cited 2017 May]. http://ir.kitepharma.com/.
   Google Scholar
• Investor Relations. Juno Therapeutics. 2017. [cited 2017 May]. http://ir.junotherapeutics.com/.
   Google Scholar
• Kudo K, Imai C, Lorenzini P, et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 2014;74:93–103.
   PubMed Web of Science ®Google Scholar
• Roybal KT, Rupp LJ, Morsut L, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164:770–779.
   PubMed Web of Science ®Google Scholar
• Wu CY, Roybal KT, Puchner EM, et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350:aab4077.
   PubMed Web of Science ®Google Scholar
• Kim MS, Ma JS, Yun H, et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc. 2015;137:2832–2835.
   PubMed Web of Science ®Google Scholar
• Rodgers DT, Mazagova M, Hampton EN, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A. 2016;113:E459–68.
   PubMed Web of Science ®Google Scholar
• Wilkie S, Van Schalkwyk MC, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32:1059–1070.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31:71–75.
   PubMed Web of Science ®Google Scholar
• Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673–1683.
   PubMed Web of Science ®Google Scholar
• Budde LE, Berger C, Lin Y, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. Plos One. 2013;8:e82742.
   PubMed Web of Science ®Google Scholar
• Neschadim A, Wang JC, Sato T, et al. Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Mol Ther. 2012;20:1002–1013.
   PubMed Web of Science ®Google Scholar
• Sato T, Neschadim A, Konrad M, et al. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther. 2007;15:962–970.
   PubMed Web of Science ®Google Scholar
• Curran KJ, Seinstra BA, Nikhamin Y, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015;23:769–778.
   PubMed Web of Science ®Google Scholar
• Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13:1440–1449.
   PubMed Web of Science ®Google Scholar
• Roybal KT, Williams JZ, Morsut L, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell. 2016;167:419-432.e16.
   PubMed Web of Science ®Google Scholar
• Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24:1160–1170.
   PubMed Web of Science ®Google Scholar
• Singh H, Figliola MJ, Dawson MJ, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011;71:3516–3527.
   PubMed Web of Science ®Google Scholar
• Perna SK, Pagliara D, Mahendravada A, et al. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014;20:131–139.
   PubMed Web of Science ®Google Scholar
• Peng W, Ye Y, Rabinovich BA, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010;16:5458–5468.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113:6392–6402.
   PubMed Web of Science ®Google Scholar
• Huang J, Liu Y, Au BC, et al. Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML. Mol Ther Methods Clin Dev. 2016;3:16074.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119:4133–4141.
   PubMed Web of Science ®Google Scholar
• Koneru M, O’Cearbhaill R, Pendharkar S, et al. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med. 2015;13:102.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Kopecky C, Hombach AA, et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71:5697–5706.
   PubMed Web of Science ®Google Scholar
• John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636–5646.
   PubMed Web of Science ®Google Scholar
• Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5:215ra172.
   PubMed Web of Science ®Google Scholar
• Ren J, Liu X, Fang C, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2016;23:2255–2266.
   PubMed Web of Science ®Google Scholar
• Qasim W, Zhan H, Samarasinghe S, et al.Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.Sci Transl Med.2017;9.
   PubMed Web of Science ®Google Scholar
• Rupp LJ, Schumann K, Roybal KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:737.
   PubMed Web of Science ®Google Scholar
• Ren J, Liu X, Fang C, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23:2255–2266.
   PubMed Web of Science ®Google Scholar
• Silva D, Tashiro H, Srinivasan M, et al. CD7 CAR for the treatment of acute myeloid and lymphoid leukemia. Blood. 2016;128:4555.
   Google Scholar